Original Research Article
Multi-Center Comparison of Medial Temporal Atrophy in Patients with Alzheimer’s Disease – Data from the ICTUS StudyGalluzzi S.a · Talassi E.a · Belussi M.a · Scheltens P.d · van de Pol L.d · Nobili F.e · Rodriguez G.e · Froelich L.f · Damian M.f · Martinez-Lage P.g · Gomez-Isla T.h · Reynish E.i-k · Ousset P.J.i-k · Vellas B.i-k · Frisoni G.B.a-c
aLENITEM Laboratory of Epidemiology, Neuroimaging and Telemedicine and bPsychogeriatric Unit, IRCCS Centro S. Giovanni di Dio Fatebenefratelli, Brescia, cAfaR, Associazione Fatebenefratelli per la Ricerca, Rome, Italy; dAlzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands; eClinical Neurophysiology, Department of Endocrinological and Medical Sciences, University of Genoa, Italy; fDivision of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany; gMemory Disturbances Unit, Neurology Department and hDepartment of Neurology and Neurosurgery, University Hospital of Navarra, University of Navarra, Pamplona, Spain; iInserm, U558, jUniversity Toulouse III, and kDepartment of Internal Medicine and Clinical Gerontology, Toulouse University Hospital, Toulouse, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Objective: To study multi-center variability of medial temporal lobe atrophy (MTA) in patients with Alzheimer’s disease (AD) recruited in a European observational study of AD. Methods: 117 mild to moderate AD patients from 5 European centers (Amsterdam, The Netherlands; Brescia and Genova, Italy; Mannheim, Germany; Pamplona, Spain) had magnetic resonance imaging scans performed as part of the routine diagnostic examination. MTA was assessed with the visual Scheltens scale. Results: AD patients from Brescia, Genova, Pamplona, and Mannheim had a mean 32% prevalence of no or borderline MTA vs. 62% of patients from Amsterdam (p = 0.002 for the difference between Amsterdam and all the other centers). The peculiar distribution of MTA in the Amsterdam patients may be attributable to younger age (70.7 ± 8.4 vs. 75.3 ± 6.8 years, p = 0.002), milder dementia severity (score 0.5 on the clinical dementia rating scale: 52 vs. 23%, p = 0.003), and less frequent depression (14 vs. 49%, p < 0.0005 in Amsterdam vs. all the other centers, respectively). Conclusion: Patients with probable AD recruited in different centers of Europe generally have similar MTA distribution, even if peculiar demographic and clinical findings might explain occasional differences. These results have implications for clinical trials in AD with biological markers as outcome measures.
© 2008 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.